Is BioNTech Stock a Buy?
_0.png?locale=de){kind=logo}
When the husband-and-wife team of Dr. Ugur Sahin and Dr. Ozlem Tureci started BioNTech (NASDAQ: BNTX), they envisioned a diversified European pharmaceutical company focused on cutting-edge cancer treatments. With the authorization and distribution of Comirnaty, the COVID-19 vaccine it developed with Pfizer (NYSE: PFE), the company will have all the resources it needs to pursue its goal.
A current $26 billion market capitalization is pricing in plenty of vaccine success, but BioNTech still may not be getting the credit it deserves for the other drugs in its pipeline using its revolutionary new messenger RNA (mRNA) approach.
Image source: Getty Images.
Source Fool.com
